
GlaxoSmithKline plc GSK
$ 53.94
-1.39%
Annual report 2025
added 03-14-2026
GlaxoSmithKline plc Interest Expense 2011-2026 | GSK
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense GlaxoSmithKline plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 912 M | 775 M | 888 M | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 912 M | 775 M | 858 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
Cabaletta Bio
CABA
|
2 M | $ 2.82 | 1.44 % | $ 283 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 2.85 | 3.26 % | $ 592 M | ||
|
Equillium
EQ
|
-76 K | $ 2.06 | - | $ 118 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.29 | -3.01 % | $ 329 M | ||
|
Stoke Therapeutics
STOK
|
9 K | $ 33.7 | -0.27 % | $ 2 B | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Heron Therapeutics
HRTX
|
1.34 M | $ 0.83 | 3.62 % | $ 138 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | ||
|
Savara
SVRA
|
4.71 M | $ 5.25 | -0.57 % | $ 1.17 B | ||
|
China SXT Pharmaceuticals
SXTC
|
1.62 M | $ 1.32 | -5.2 % | $ 1.88 M | ||
|
Kala Pharmaceuticals
KALA
|
-4.26 M | $ 0.2 | -6.67 % | $ 759 K | ||
|
Tarsus Pharmaceuticals
TARS
|
-202 K | $ 67.2 | 0.36 % | $ 2.81 B | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 47.55 | 0.98 % | $ 4.28 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.45 | -1.77 % | $ 853 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M |